PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod

Novartis

Status: Completed

Conditions: Relapsing Remitting Multiple Sclerosis

Study type: Observational

Funder types: Industry

Identifiers

NCT02335892

CFTY720DGB04

Details and patient eligibility

About

Multi centre, prospective, non interventional study in 200-240 UK relapsing remitting multiple sclerosis patients. Patients will complete questionnaires at baseline, 3, 6 and 12 months.

Full description

Multi centre, prospective, non interventional study in 200-240 UK relapsing remitting multiple sclerosis patients assessing the change in QoL and PRO outcome measures from baseline to 12 months after starting fingolimod. Patients will complete 4 questionnaires at baseline (prior to first fingolimod dose), then repeat them at 3, 6 and 12 month intervals via post.

Enrollment: 114 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients prescribed Gilenya within the EU licence No previous exposure to Gilenya Patient's HCP considers patient able to complete study questionnaires Patient is between 18-55 years of age -

Exclusion criteria

There are no exclusion criteria for this study.